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positive samples, being underestimated by Ig/TCR method in
25 cases and by m-BCR/ABL quantiﬁcation in 21 cases. We
found signiﬁcantly more false-negative samples by Ig/TCR ap-
proach (70 samples) compared to BCR/ABL quantiﬁcation (20
samples). Altogether, we tested 219 bone marrow (BM), 130
peripheral blood (PB) and 1 cerebrospinal ﬂuid samples. The PB
samples showed signiﬁcantly worse correlation between the two
methods compared to BM (p0.02). In our hands, the quanti-
ﬁcation of BCR/ABL transcripts appears to be a more reliable
method than the generally accepted Ig/TCR-based MRD mon-
itoring as the number of false-negative samples by BCR/ABL
quantiﬁcation is signiﬁcantly lower. This contention is sup-
ported by outcome of our patients who subsequently underwent
allogeneic SCT. In this group BCR/ABL positivity preceding
allogeneic SCT seems to represent a better predictor of subse-
quent relapse than Ig/TCR approach.
Supported by VZ MZO 00064203.
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FLUDARABINE AND TREOSULFAN; A NOVEL REDUCED-TOXICITY REG-
IMEN WITH EFFECTIVE ANTI-LEUKEMIA ACTIVITY IN PATIENTS WITH
AML AND MDS
Shimoni, A.1, Hardan, I.1, Shem-Tov, N.1, Yerushalmi, R.1,
Nagler, A.1 1Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Allogeneic stem-cell transplantation (SCT) is a potentially cura-
tive treatment for patients (pts) with AML and MDS. However, it
may be associated with signiﬁcant toxicity. New regimens are
continuously explored trying to reduce toxicity while retaining
anti-leukemia effect. Treosulfan is a prodrug of a bifunctional
alkylating cytotoxic agent used in the past for the treatment of
ovarian cancer. In-vitro it mediates cytotoxicity against cell lines of
a variety of hematological malignancies including acute leukemia.
In escalated doses it shows myeloablative as well as immunosup-
pressive properties. Initial studies in SCT showed promising re-
sults with relatively limited extramedullary toxicity. In the current
study we explored a regimen of ﬂudarabine (total dose 150 mg/m2)
and treosulfan (12 gr/m2  3) in pts with AML and MDS not
eligible for standard SCT. The study included 24 pts, 15 male, 9
female. The median age was 55 years (range, 30-69). Nineteen had
AML (8 secondary, 5 to MDS, 1 to myeloﬁbrosis, 1 to breast
cancer, 1 to NHL), 5 had MDS. Two pts had a prior autologous
SCT (1 for NHL and 1 for AML). All pts had chemo-sensitive or
untreated disease at the time of SCT; 11 pts were in CR1, 5 in
CR2/3, 6 previously untreated and 2 in untreated relapse. The
donor was an HLA matched sibling (n11) or matched unrelated
(n13). Twenty-one pts engrafted, one later rejected the graft.
Three pts died prior to engraftment. The median time to ANC
0.5  109/ L and platelet 20  109 / L was 15 days (range, 11-21)
and 16 days (range, 11-50), respectively. With a median follow-up
of 12 months (range, 1-27), 16 pts are alive in CR, one of them in
CR 4 months following treatment for post SCT relapse. Eight pts
died (relapse-2, organ toxicity – 2, sepsis - 2, CNS bleeding - 1,
graft rejection - 1). The cumulative incidence of acute and chronic
GVHD was 20% and 41%, respectively. The estimated 1-year
overall and disease-free survival were 66% (95% CI, 11-43) and
63% (95% CI, 11-42), respectively. The cumulative incidence of
relapse at 1- year after SCT is 11% (95% CI, 3-41) and the
cumulative incidence of non-relapse mortality at 1 year is 26%
(95% CI, 13-52). In conclusion, the combination of ﬂudarabine
and treosulfan is relatively safe, with effective anti-leukemia po-
tential, in pts not eligible for myeloablative conditioning. This
regimen merits further study in larger scale studies.
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REDUCED INTENSITY STEM CELL TRANSPLANT (RIST) AS SALVAGE
TREATMENT FOR RELAPSE FOLLOWING MYELOABLATIVE ALLOGE-
NEIC TRANSPLANTATION IN ADULT ACUTE MYELOID LEUKEMIA
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Relapse of acute myeloid leukemia (AML) following myeloabla-
tive allogeneic stem cell transplantation portends a dismal prog-
nosis. Therapy aimed at enhancing graft-versus-leukemia (GVL)
effect, e.g., by donor leukocyte infusion, has limited success in
AML, and a second ablative transplant is associated with prohibi-
tive mortality in adults. From April 2001 to March 2006, nine
patients, ranging in age from 21 to 57, with high risk myeloid
malignancy (7 AML and 2 advanced myelodysplasia) and overt
bone marrow relapse less than one year after ablative busulfan/
cyclophosphamide conditioning have been treated with a cytore-
ductive regimen of ﬂudarabine (30 mg/m2/day) and cytarabine
(2g/m2/day) for 5 days (-7 through -3) and G-CSF administration
(5 ug/kg daily starting day -8) with or without idarubicin (8 mg/m2
days -7, -5, and -3) (8 cases) or ﬂudarabine 30 mg/m2 for 3 days
and 200 cGy total body irradiation (1 case). G-CSF mobilized
peripheral blood stem cells from their original HLA-matched
donor (8 siblings, 1 unrelated) were infused. Graft versus host
disease (GVHD) prophylaxis was mycophenolate mofetil for 30
days and cyclosporine with a rapid taper. The mean onset of
relapse after the initial ablative transplant was day 172 (range
106-271). Fludarabine-based therapy was well tolerated with no
treatment related mortality. Full donor chimerism was established
by day 72 (range 26-113) in 6 patients (67%). Five patients died: 2
from relapse without GVHD at day 30 and 301 after RIST
(one patient with complex and one with Ph cytogenetic abnor-
malities), 3 from relapse with evidence of GVHD. Four patients
survive: one has relapsed at 91 days after RIST and is receiving
alternate therapy, while three patients (30%) survive in complete
remission at 100, 635 and 1795 days after salvage RIST. In 5
cases (56%), the duration of complete remission after RIST was
longer than after the initial ablative transplant. We conclude that
ﬂudarabine-based RIST is a safe and effective salvage therapy
offering a chance for increased survival with low morbidity in
patients relapsing after ablative transplant. In addition, RIST ther-
apy has resulted in long-term disease free survival in over 20% of
cases in this study.
368
LONGER FOLLOW UP OF PATIENTS (PTS) WITH ADVANCED CHRONIC
LYMPHOCYTIC LEUKEMIA (CLL) TREATED WITH NONMYELOABLATIVE
CONDITIONING AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLAN-
TATION (HCT)
Sorror, M.L.1, Storer, B.1,2, Sandmaier, B.M.1,2, Maris, M.B.1,2,
Shizuru, J.4, Niederwieser, D.5, Agura, E.6, Chauncey, T.3,
Maziarz, R.7, Pulsipher, M.8, McSweeney, P.9, Wade, J.10,
Bruno, B.11, Langston, A.12, Blume, K.4, Storb, R.1,2, Maloney, D.G.1,2
1Fred Hutchinson Cancer Research Center; 2University of Washington;
3Seattle Veterans Administration Medical Center, Seattle, WA; 4Stan-
ford University, Palo Alto, CA; 5University of Leipzig, Leipzig, Ger-
many; 6Baylor University, Dallas, TX; 7Oregon Health & Sciences
University, Portland, OR; 8University of Utah, Salt Lake City, UT;
9University of Colorado, Denver, CO; 10Medical College of Wisconsin,
Milwaukee, WI; 11University of Torino, Torino, Italy; 12Emory Uni-
versity, Atlanta, GA.
Pts with ﬂudarabine-refractory CLL have a poor prognosis with
conventional therapies with median survival of 12 months. We
previously reported 2-year overall survival of 60% for 64 pts
treated with nonablative HCT from related (n44) or unrelated
(n20) donors (Sorror et al. JCO 2005, 23: 3819). Here, we
present an update on the ﬁrst 64 pts (median of 48 [range: 24-86]
months) and report data on 18 additional pts transplanted between
February 2004 and January 2006. The 82 pts were given nonabla-
tive HCT from related (n52) or unrelated donors (n30). Me-
dian pt age was 55.5 (range 42-72) years, and the median number
of prior regimens was 4 (range 1-12). Seventy-nine pts were re-
fractory to at least 1 regimen, 72 to ﬂudarabine (FLU), 27 to
alkylating agents, 23 to rituxumab, 7 to CAMPATH®, and 3 had
failed high-dose autologous HCT. Thirty-six pts (44%) had dis-
ease responsive to the last chemotherapy [36% partial (PR) and 7%
complete remission (CR)] while 37 were resistant and 9 had un-
tested relapse. Conditioning for HCT consisted of 2 Gy TBI alone
(n13) or combined with FLU (n69), 90 mg/m2. All pts received
G-PBMC. The incidences of grades II, III, and IV acute GVHD
were 40%, 16%, and 2% respectively, and chronic extensive
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GVHD was 53% at 4-years. The overall response rate was 74%
(53% CR). Unrelated recipients had a trend for higher CR rate
than related recipients (Table). Overall, 45 patients are alive; 27 in
CR, 1 with minimal residual disease, 7 in PR, 2 with stable disease,
and 8 with relapse/progression. Thirty-seven pts died, 17 from
progression/relapse, 14 from infections  GVHD, 2 from cardiac
causes, 1 from metastatic lung cancer, 1 from cerebral stroke, 1
from rejection and aplasia, and one during open heart surgery for
a valve defect. Estimated 4-year rates of non-relapse mortality,
relapse, disease free, and overall survivals were 24%, 32%, 44%,
and 55% respectively. Among 31 surviving pts with the longest
follow up (24-86 months), 21 had developed chronic GVHD.
Fifteen of the 21 (median follow up of 49 months) had immuno-
suppression discontinued upon resolution of chronic GVHD while
6 (median follow up of 43 months) continued on immunosuppres-
sion. The median performance status (PS) of the 21 pts was 90%.
Nonmyeloablative HCT resulted in median survival of greater
than 4 years for pts with ﬂudarabine-refractory CLL. Pts with
longer follow up showed sustained remissions and continuing res-
olution of chronic GVHD with good performance status.
Table: Results stratiﬁed by donor type
Donor
Related
(n  52)
Unrelated
(n  30) p
Acute GVHD grade
II, III, and IV
39%, 14%,
and 2%
43%, 20%,
and 3%
0.19
Chronic extensive
GVHD at 4-years
51% 56% 0.94
Pts off
immunosuppression
at 3 years after
chronic GVHD
29% 52% 0.16
Pts alive and off
immunosuppression
at 4 years
29% 70%*
CR rate at 4-years 47% 63% 0.07
Relapse/progression
at 4-years
33% 31% 0.45
Surviving pts 13 CR, 1
MRD, 6
PR, 2
stable,
and 4
progression
14 CR, 1
PR, 2
progression,
and 2
relapse
Day-100 non-relapse
mortality
8% 10% 0.97
4-year non-relapse
mortality
23% 24% 0.97
4-year relapse-related
mortality
27% 12% 0.35
4-year disease-free
survival
43% 45% 0.59
4-year overall survival 50% 64% 0.62
*This is a temporary spike at exactly 4.0 years. The prevalence at
3.9 and 4.1 years is 53%. MRD indicates minimal residual
disease.
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Reduced-intensity allogeneic stem cell transplantation (SCT) re-
lies mainly on graft versus leukemia (GVL) for its efﬁcacy; is
increasingly being used for treatment of hematological malignan-
cies. The role of GVL is less deﬁned in transplantation for acute
lymphoblastic leukemia (ALL). We report the experience of 21
ALL patients who were treated with ﬂudarabine 25mg/m2 daily for
5 days and melphalan 140 mg/m2 followed by Allo-SCT between
5/7/02 and 5/31/06. The indications for the reduced-intensity
regimen were: 1) previous Allo-SCT 5(24%), 2) 50 years 7(33%)
and 3) decreased organ function 9(43%). The patient/treatment
characteristics are: median age 46 years (6-68), remission status at
Allo-SCT: 1CR 10(48%), 1RL 3(14%), 2CR 4(19%) and 3CR
4(19%), Ph ALL 11(52%), donor type: match sibling 7(33%),
matched unrelated 14(67%), stem cell source: primed peripheral
stem cells 20(95%) and cord blood-double 1(5%), graft versus host
disease (GVHD) prophylaxis: cyclosporine(CSA)/methotrex-
ate(MTX) 4(19%), CSA/Mycophenylate(MMF) 9(43%), CSA/
ATG 1(5%) and CSA/MMF/MTX 1(5%). Six (28%) patients
received tacrolimus and sirolimus. With a median follow-up for
alive patients 17.0 months (range: 2.7-47.2), the one-year cumula-
tive probability of overall survival, disease-free survival and relapse
rate were 77.4% (95%CI: 57.2, 88.9), 70.9% (95%CI: 52.0, 83.4)
and 7.7% (95%CI: 1.3, 38.7) respectively. Incidence of acute
GVHD was 50% for grade II-IV and 15% for grade III-IV. Of the
patients evaluable for chronic GVHD, 11% developed limited
chronic GVHD and 33% developed extensive chronic GVHD.
The 100 day non-relapse mortality was 10%. The results of this
study show that RI Allo-SCT using ﬂudarabine/melphalan based
conditioning is a potential therapeutic approach for patients with
high-risk ALL who are not eligible for full intensity transplant.
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Background-purpose: The use of reduced intensity conditioning
regimen (RIC) may reduce non-relapse mortality (NRM) and allow
long term disease free survival (DFS) and overall survival (OS)
through graft versus leukemia (GVL) effect in patients considered not
eligible for convenitonal allogeneic stem cell transplantation (Allo-
SCT). In this multicenter, prospective study we report our experience
wit RIC regimen based on ﬂudarabine and busulfan. Patients and
methods: We included all 93 consecutive patients with AML and
MDS who underwent ﬂudarabine-busulphan RIC-Allo-SCT from an
HLA identical sibling, in 6 Spanish centers since 1998 to 2005.
Diagnoses were acute myeloid leukemia (AML) (n59) or myelodis-
plastic syndrome (MDS) (n34), median time from diagnostic was 6
(range 1-150) months. Median age was 58 (range 21-70) years. Follow
up for survivors was 43 months (3-89). Conditioning regimen con-
sisted of ﬂudarabine 150 mg/m2 and busulfan 8-10 mg/kg. Graft
versus host disease prophylaxis consisted of cyclosporin A and a short
course of methotrexate or mycofenolate mofetil. Results: These pa-
tients received a RIC regimen for advanced age /-comorbidities
(83%) previous SCT/- advanced age (9%) or active infection, poor
PS, or other comorbidities (8%). 56% of patients showed very high
risk disease (high risk karyotype, refractory disease or high risk IPSS).
Median time to neutrophil and platelet recovery was on day 17
(range7-27) and 11 (range 0-59) days respectively. Thirty three pa-
tients developed acute GVHD for a Cumulative Incidence (Cum Inc)
of 33% (95%CI 25-44) and 53 out of 77 evaluable patients developed
chronic GVHD for a Cum Inc of 54% (95% CI 44-65%). The
100-day and 1-year Cum Inc NRM was 8% and 17% respectively.
The 4 Years Relapse Cum Inc was 37% (95% CI 28-50%). The
4-years DFS was 43% (33-53%) for the whole group. The 4-year
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